SCHEMBL70823

SCHEMBL70823

COc1cc(OC)c(OC)c(O)c1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.58
CYP3A4 P08684 1/20 0.58
ERN1 O75460 1/20 0.48
ACHE P22303 1/20 0.48
GRIN2D O15399 1/20 0.47
GRIN3B O60391 1/20 0.47
GRIN1 Q05586 1/20 0.47
GRIN2A Q12879 1/20 0.47
GRIN2B Q13224 1/20 0.47
GRIN2C Q14957 1/20 0.47
GRIN3A Q8TCU5 1/20 0.47
CA9 Q16790 3/20 0.46
CA12 O43570 2/20 0.45
CA1 P00915 2/20 0.45
PKM P14618 2/20 0.45
CA7 P43166 2/20 0.45
CA2 P00918 1/20 0.45
CA3 P07451 1/20 0.45
CA4 P22748 1/20 0.45
CA6 P23280 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27497325 0.90 MAPT (0.64) MAPTCYP3A4ERN1ACHEGRIN2D
SCHEMBL27553867 0.85 MAPT (0.58) MAPTCYP3A4ERN1ACHEGRIN2D
SCHEMBL11881848 0.83 MAPT (0.56) MAPTCYP3A4ERN1ACHEGRIN2D
SCHEMBL684134 0.81 MAPT (0.48) MAPTCYP3A4ERN1ACHECA9
SCHEMBL4127825 0.81 MAPT (0.54) MAPTCYP3A4ERN1ACHEGRIN2D
SCHEMBL29287619 0.81 CYP3A4 (0.55) MAPTCYP3A4ERN1ACHEGRIN2D
SCHEMBL17666196 0.78 ERN1 (0.67) MAPTCYP3A4ERN1ACHECA9
SCHEMBL679526 0.75 ACHE (0.60) MAPTCYP3A4ACHECA9PTGS2
SCHEMBL12587650 0.75 MAPT (0.52) MAPTCYP3A4ERN1ACHEGRIN2D
SCHEMBL28020131 0.74 ERN1 (0.62) MAPTERN1LMNATDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2311472-B1 COGNITIVE DISORDER-AMELIORATING AGENT JAPAN ROYAL JELLY CO LTD (JP) 2014-03-05 EP disclosed
EP-2311472-B1 COGNITIVE DISORDER-AMELIORATING AGENT JAPAN ROYAL JELLY CO LTD (JP) 2014-03-05 EP disclosed
US-20130129832-A1 COGNITIVE IMPAIRMENT AMELIORANT TOHOKU UNIVERSITY (JP) 2013-05-23 US disclosed
US-20130129832-A1 COGNITIVE IMPAIRMENT AMELIORANT TOHOKU UNIVERSITY (JP) 2013-05-23 US disclosed
EP-2479203-A1 AROMATIC POLYESTER Muroran Institute of Technology (JP) 2012-07-25 EP disclosed
US-20120172570-A1 AROMATIC POLYESTER NITTA CORPORATION 2012-07-05 US disclosed
US-8129493-B2 Aromatic polyester MURORAN INSTITUTE OF TECHNOLOGY (JP) 2012-03-06 US disclosed
US-20110287106-A1 COGNITIVE IMPAIRMENT AMELIORANT JAPAN ROYAL JELLEY CO., LTD. (JP) 2011-11-24 US disclosed
US-20110287106-A1 COGNITIVE IMPAIRMENT AMELIORANT JAPAN ROYAL JELLEY CO., LTD. (JP) 2011-11-24 US disclosed
US-20110224343-A1 MODIFIER FOR AROMATIC POLYESTER AND AROMATIC POLYESTER RESIN COMPOSITION COMPRISING THE SAME MURORAN INSTITUTE OF TECHNOLOGY (JP) 2011-09-15 US disclosed
US-20110092662-A1 AROMATIC POLYESTER NITTA CORPORATION (JP) 2011-04-21 US disclosed
EP-2311472-A1 COGNITIVE DISORDER-AMELIORATING AGENT Japan Royal Jelly Co., Ltd. (JP) 2011-04-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224343-A1 MODIFIER FOR AROMATIC POLYESTER AND AROMATIC POLYESTER RESIN COMPOSITION COMPRISING THE SAME F12, PHAX, WDR82 MAPT 1923/4885CYP3A4 2028/4885ERN1 3196/4885
US-20130129832-A1 COGNITIVE IMPAIRMENT AMELIORANT CHAT, ACHE, PSEN1 MAPT 7/4885CYP3A4 4098/4885ERN1 1385/4885
US-20110287106-A1 COGNITIVE IMPAIRMENT AMELIORANT CHAT, ACHE, PSEN1 MAPT 7/4885CYP3A4 4098/4885ERN1 1385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.